butenafine has been researched along with Leishmaniasis, Cutaneous in 1 studies
butenafine: studied on experimental dermatophytosis
butenafine : Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections.
Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bezerra-Souza, A | 1 |
| Jesus, JA | 1 |
| Laurenti, MD | 1 |
| Lalatsa, A | 1 |
| Serrano, DR | 1 |
| Passero, LFD | 1 |
1 other study available for butenafine and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Antifungal Agents; Benzylamines; Drug De | 2021 |